RNA Editors, Cofactors, and mRNA Targets: An Overview of the C-to-U RNA Editing Machinery and Its Implication in Human Disease

Taga Lerner; F Nina Papavasiliou; Riccardo Pecori

doi:10.3390/genes10010013

RNA Editors, Cofactors, and mRNA Targets: An Overview of the C-to-U RNA Editing Machinery and Its Implication in Human Disease

Genes (Basel). 2018 Dec 27;10(1):13. doi: 10.3390/genes10010013.

Authors

Taga Lerner^{1

2}, F Nina Papavasiliou³, Riccardo Pecori⁴

Affiliations

¹ Division of Immune Diversity, Program in Cancer Immunology, German Cancer Research Centre, 69120 Heidelberg, Germany. t.lerner@dkfz-heidelberg.de.
² Division of Biosciences, Uni Heidelberg, 69120 Heidelberg, Germany. t.lerner@dkfz-heidelberg.de.
³ Division of Immune Diversity, Program in Cancer Immunology, German Cancer Research Centre, 69120 Heidelberg, Germany. n.papavasiliou@dkfz-heidelberg.de.
⁴ Division of Immune Diversity, Program in Cancer Immunology, German Cancer Research Centre, 69120 Heidelberg, Germany. r.pecori@dkfz-heidelberg.de.

Abstract

One of the most prevalent epitranscriptomic modifications is RNA editing. In higher eukaryotes, RNA editing is catalyzed by one of two classes of deaminases: ADAR family enzymes that catalyze A-to-I (read as G) editing, and AID/APOBEC family enzymes that catalyze C-to-U. ADAR-catalyzed deamination has been studied extensively. Here we focus on AID/APOBEC-catalyzed editing, and review the emergent knowledge regarding C-to-U editing consequences in the context of human disease.

Keywords: AID/APOBEC; RNA editing; epitranscriptome; neurological disorders.

Publication types

Review